Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

22.67 -1.39 (-5.78%)
Streaming Delayed Price Updated: 10:47 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Harrow Announces Third Quarter 2022 Financial Results
From Harrow
Via Business Wire
Harrow Launches Atropine.com
From Harrow
Via Business Wire
Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
From Harrow
Via Business Wire
FDA Approves First Branded Ocular Anesthetic In Almost 14 Years
Via Benzinga
Recap: Harrow Health Q2 Earnings
  Harrow Health (NASDAQ:HROW) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300
From Melt Pharmaceuticals, Inc.
Via Business Wire
NGM Biopharmaceuticals, Fox Corporation And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Harrow Sells Non-Ophthalmic Compounding Business
From Harrow
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. 
Via Benzinga
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
From Harrow
Via Business Wire
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Ryder System, Harrow Health And Other Big Gainers From Tuesday
U.S. stocks closed mixed with the Dow Jones dropping around 125 points on Tuesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
From Harrow
Via Business Wire
Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
From Harrow Health, Inc.
Via Business Wire
Harrow Health Announces Second Quarter 2022 Financial Results
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022
From Harrow Health, Inc.
Via Business Wire
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
From Harrow Health, Inc.
Via Business Wire
7 Mighty Micro-Cap Stocks That Could Be Future Moonshots
These seven micro-cap stocks, either due to catalysts or a low valuation, could make a move to substantially higher prices. 
Via InvestorPlace
Harrow Health Announces First Quarter 2022 Financial Results
From Harrow Health, Inc.
Via Business Wire
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
From Melt Pharmaceuticals, Inc.
Via Business Wire
Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022
From Harrow Health, Inc.
Via Business Wire
Harrow Health Announces Appointments to Its Board of Directors
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022
From Harrow Health, Inc.
Via Business Wire
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
From Harrow Health, Inc.
Via Business Wire
Harrow Health to Present at Aegis Virtual Conference
From Harrow Health, Inc.
Via Business Wire
Two Insider Moonshots Rising on Sudden Buying
Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future. 
Via InvestorPlace
Harrow Health Publishes Corporate Transparency Report
From Harrow Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.